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The treatment of opiate dependence is no longer limited to abstinence but is also based on 
maintenance therapies. Opiate maintenance therapies differ widely in their methods and purposes. 
Several pharmacological agents, partial or complete agonists, are currently available: methadone, 
buprenorphine, LAAM (levo-alpha acetylmethadol) but also codeine. In addition, several other 
compounds have been used in a more limited manner, such as dextromoramide, morphine, ... For all 
these substances, there is a wide variability in dosages and treatment duration, but also in objective 
and subjective effects. In this context, it is important to precise the respective role of the various 
agents in the treatment of opiate addiction. 
Methods  
We performed meta-analyses according to the methods defined by Cucherat (1997). The main 
objective was to compare the relative efficacy of the maintenance treatments. In addition, we wanted 
to evaluate the importance of the dosages, the role of the duration (less vs more than 5 months) and of 
the origin of the studies (USA vs rest of the world), the influence of associated psychosocial 
interventions and pharmacological therapies such as disulfiram, desipramine, or buspirone. Selected 
studies were randomised controlled trial (RCT) comparing at least 2 maintenance treatments in opiate 
addicts. Two main parameters of efficacy were used: retention in treatment groups and abstinence 
from illicit opiates. The results were controlled for publication biases using the funnel plot method. 
Results  
From a total of 1902 studies, 28 were selected for the evaluation of maintenance treatments, 11 for the 
influence of psychosocial interventions and 4 for the role of associated therapies. Methadone was 
found superior to placebo both in retention (p < 0.001) and abstinence (p < 0.001). Buprenorphine was 
also significantly better than placebo in both criteria (p < 0.001 and p < 0.001). Methadone was 
superior to buprenorphine in retention (p < 0.002) but a trend in the opposite direction was observed 
for abstinence (p = 0.09). No difference was present between methadone and LAAM. Regarding the 
duration of the studies, results showed a significant effect favoring methadone over buprenorphine in 
studies longer than 5 months. Studies performed in the USA exhibited a statistically less important 
effect for methadone as compared to studies performed in the rest of the world, even if methadone was 
effective in both areas. Regarding dosages, a higher dose of methadone (60 mg/d or more) was 
associated with better retention (p = 0.04) and abstinence (p = 0.003). Similarly, higher dosages of 
buprenorphine (7 mg/d or more) demonstrated better outcomes regarding both retention (p = 0.04) and 
abstinence (p = 0.047). Higher dosages of LAAM exhibited a trend toward better results in abstinence 
(p = 0.06) but not retention. Finally, psychosocial interventions as well as associated therapies did not 
influence significantly the outcome. 
Conclusion 
These meta-analyses support the efficacy of maintenance treatment in opiate addiction. The two main 
substances appear different in their efficacy, with methadone associated with better retention in the 
program and buprenorphine with a higher rate of abstinence. 
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